Haemacure Reports Third Quarter 20...( MONTREAL Aug. 31 / Haemacure Corp...),Health

MONTREAL, Aug. 31 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX : HAE) released today the results of its third quarter ended July 31, 2007.

Results

Revenues amounted to $31,674, as compared to $31,409 for the same quarter last year. Revenues are exclusively derived from the sale of our fibrin sealant application devices. Operating expenses amounted to $869,822, as compared to $741,205 for the same quarter last year. The increase is mainly attributable to stock-based compensation resulting from option grants and increased business development and investor relations activities. The consolidated net loss for the quarter amounted to $856,879, or $0.01 per share, as compared to $724,163, or $0.02 per share, for the same quarter last year.

"We continue to accomplish the turnaround of the company to make it an independent player with next generation, high-value products", said Mr. Joseph Galli, Chairman and Chief Executive Officer of Haemacure. "We are implementing a strategy to hasten the initiation of the Phase III clinical trials for our lead product candidate, the Hemaseel(R)HMN fibrin sealant We are also assessing alliances with strategic partners that may result in much wider fields of use for our fibrin sealant. To that end, we will soon deliver to these potential partners small volumes of our fibrin sealant for evaluation", concluded Mr. Galli.

Financial Position

Cash and cash equivalents and temporary investments stood at $8.3 million as of July 31, 2007, as compared to $519,300 as at October 31, 2006.

Other

Pursuant to an agreement entered into in 2002, CSL Behring AG ("CSL") is obligated to pay to Haemacure the sum of US$4.5 million upon Haemacure achieving certain milestones related to its Hemaseel project. On August 20, 2007, CSL advised Haemacure of its opinion that it is no longer obliged to pay this sum. Haemacure disputes the position of CSL and will aggressively defend its right to the future payment
'/>"/>